An open-label extension study to determine the safety of pirnavanserin in patients with Parkinson's disease and psychosis

被引：0
|
作者：
Mills, R.
Johnson, A.
Bahr, D.
Williams, H.
Revell, S.
机构：
来源：
MOVEMENT DISORDERS | 2008年 / 23卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
672
引用
收藏
页码：S221 / S221
页数：1
相关论文
共 50 条
  • [1] An open-label extension study to determine the safety of pimavanserin in patients with Parkinson's disease and psychosis
    Mills, R.
    Johnson, A. D.
    Bahr, D.
    Williams, H.
    Revell, S.
    MOVEMENT DISORDERS, 2009, 24 : S268 - S269
  • [2] An Open-Label Extension Study To Determine the Safety of Pimavanserin in Patients with Parkinson's Disease and Psychosis
    Mills, Roger
    Johnson, Ann D.
    Williams, Hilde
    Bahr, Daun
    Revell, Stephen
    NEUROLOGY, 2009, 72 (11) : A319 - A319
  • [3] Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients
    Isaacson, Stuart H.
    Ballard, Clive G.
    Kreitzman, David L.
    Coate, Bruce
    Norton, James C.
    Fernandez, Hubert H.
    Ilic, Tihomir V.
    Azulay, Jean-Philippe
    Ferreira, Joaquim J.
    Abler, Victor
    Stankovic, Srdjan
    PARKINSONISM & RELATED DISORDERS, 2021, 87 : 25 - 31
  • [4] An open-label extension study to evaluate the safety of ropinirole prolonged release in Chinese patients with advanced Parkinson's disease
    Zhang, Zhenxin
    Wang, Jian
    Zhang, Xiaoying
    Chen, Shengdi
    Wang, Zhenfu
    Zhang, Baorong
    Liu, Chunfeng
    Qu, Qiumin
    Cheng, Yan
    Zhu, Rongxuan
    Li, Jie
    Hu, Jingqiu
    Cai, Meng
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (04) : 723 - 730
  • [5] An open-label extension study of modafinil for the treatment of daytime sleepiness in patients with Parkinson's disease
    Adler, CH
    Caviness, JN
    Hentz, JG
    Lind, M
    Tiede, J
    SLEEP, 2002, 25 : A251 - A252
  • [6] An interim analysis of an open-label extension study to examine the long-term safety and tolerability of pimavanserin in the treatment of Parkinson's disease psychosis
    Mills, R.
    Bahr, D.
    Williams, H.
    Peters, P.
    Isaacson, S.
    MOVEMENT DISORDERS, 2010, 25 (07) : S302 - S302
  • [7] Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
    Friedman, Joseph H.
    Berman, Robert M.
    Goetz, Christopher G.
    Factor, Stewart A.
    Ondo, William G.
    Wojcieszek, Joanne
    Carson, William H.
    Marcus, Ronald N.
    MOVEMENT DISORDERS, 2006, 21 (12) : 2078 - 2081
  • [8] Long-term Evaluation of Open-label Pimavanserin Safety and Tolerability in Parkinson's Disease Psychosis
    Ballard, Clive
    Kreitzman, David
    Isaacson, Stuart
    Norton, James
    Demos, George
    Liu, I-Yuan
    Fernandez, Hubert
    Ilic, Tihomir
    Azulay, Jean
    Ferreira, Joaquim
    Abler, Victor
    Stankovic, Srdjan
    NEUROLOGY, 2020, 94 (15)
  • [9] Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis
    Ballard, Clive G.
    Kreitzman, David L.
    Isaacson, Stuart
    Liu, I-Yuan
    Norton, James C.
    Demos, George
    Fernandez, Hubert H.
    Ilic, Tihomir V.
    Azulay, Jean-Philippe
    Ferreira, Joaquim J.
    Abler, Victor
    Stankovic, Srdjan
    PARKINSONISM & RELATED DISORDERS, 2020, 77 : 100 - 106
  • [10] Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study
    Espay, Alberto J.
    Hauser, Robert A.
    Dhall, Rohit
    Thakkar, Sandeep
    Cloud, Leslie
    Zeitlin, Leonid
    Banisadr, Ghazal
    Fisher, Stanley
    Visser, Hester
    MOVEMENT DISORDERS, 2024, 39 (02) : 428 - 432
12345